12:00 AM
 | 
May 19, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aerosolized Alpha-1 antitrypsin: Phase II/III data

Top-line data from a double-blind, European and Canadian Phase II/III trial in 168 patients with AAT deficiency showed that twice-daily 160 mg inhaled AAT missed the primary endpoint of improving time to first moderate or severe exacerbation at 1 year vs. placebo. Kamada said inhaled AAT did reduce the frequency...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >